Robert W. Baird Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock Price

Enliven Therapeutics (NASDAQ:ELVN) had its price objective lifted by equities researchers at Robert W. Baird from $32.00 to $40.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Robert W. Baird’s target price indicates a potential upside of 60.51% from the company’s previous close.

Separately, HC Wainwright reissued a “buy” rating and set a $37.00 price objective on shares of Enliven Therapeutics in a report on Tuesday, October 1st.

Enliven Therapeutics Trading Down 3.4 %

Shares of Enliven Therapeutics stock opened at $24.92 on Friday. The company’s fifty day simple moving average is $26.16 and its 200-day simple moving average is $23.88. Enliven Therapeutics has a 1 year low of $9.80 and a 1 year high of $30.03. The company has a market cap of $1.18 billion, a price-to-earnings ratio of -13.12 and a beta of 1.08.

Enliven Therapeutics (NASDAQ:ELVN) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.17. As a group, research analysts forecast that Enliven Therapeutics will post -1.98 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Joseph P. Lyssikatos sold 12,000 shares of the firm’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $22.49, for a total transaction of $269,880.00. Following the sale, the insider now directly owns 1,077,936 shares in the company, valued at $24,242,780.64. This trade represents a 1.10 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Benjamin Hohl sold 6,250 shares of the business’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $28.56, for a total value of $178,500.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 152,195 shares of company stock worth $4,091,454. Insiders own 29.20% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in ELVN. Quest Partners LLC boosted its stake in shares of Enliven Therapeutics by 87.3% during the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after acquiring an additional 742 shares during the period. EntryPoint Capital LLC acquired a new stake in Enliven Therapeutics during the 1st quarter valued at $167,000. China Universal Asset Management Co. Ltd. boosted its position in Enliven Therapeutics by 64.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock worth $232,000 after purchasing an additional 3,559 shares during the period. SG Americas Securities LLC acquired a new position in shares of Enliven Therapeutics in the third quarter valued at $256,000. Finally, Verition Fund Management LLC bought a new position in shares of Enliven Therapeutics in the third quarter valued at about $271,000. Institutional investors own 95.08% of the company’s stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.